Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Targovax ASA ( (GB:0RIS) ) just unveiled an update.
Circio Holding ASA has detailed the allocation of new shares and corresponding warrants to key executives, board members and their closely associated entities following the completion of its recently announced rights issue and private placement. The CEO, CFO’s associated company, and other members of the management team and board received substantial allotments, including additional shares and warrants as commission for their pre-subscriptions, underscoring strong insider participation in the capital raising. The transaction strengthens Circio’s capital base as it pursues development of its circVec circular RNA platform and continues cost-efficient work on its TG01 cancer vaccine program, aligning management’s financial interests more closely with those of shareholders and signaling internal confidence in the company’s long-term strategy.
More about Targovax ASA
Circio Holding ASA is a Norwegian biotechnology company focused on developing novel circular RNA (circRNA) expression technology for gene and cell therapies. Through its proprietary circVec platform, developed by wholly owned subsidiary Circio AB in Stockholm, the company targets next-generation RNA, DNA and viral therapeutics, aiming to deliver significantly prolonged RNA stability and enhanced protein expression for applications in genetic medicine, cell therapy and chronic diseases. Circio is also advancing its legacy TG01 immuno-oncology program for RAS-mutated cancers via external academic and industry collaborations in ongoing clinical trials in Norway and the United States.
Average Trading Volume: 3,884,203
Current Market Cap: NOK204.5M
Find detailed analytics on 0RIS stock on TipRanks’ Stock Analysis page.